Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Rebetol Is Only “Medically Necessary” Oral Product In FDA Decree

Executive Summary

Schering-Plough's Rebetol (ribavirin capsules) is the only oral product deemed "medically necessary" under the company's consent decree with FDA

You may also be interested in...



Schering Sales Force Recruitment Is 80% Complete; Morale Remains High

Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26

Schering Sales Force Recruitment Is 80% Complete; Morale Remains High

Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26

Schering GMPs: Over 25% Of Consent Decree Steps Complete, Company Says

Schering-Plough is over a quarter of the way through fulfilling its requirements under a 2002 consent decree

Related Content

UsernamePublicRestriction

Register

PS039917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel